Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 6, 2024
Daily News
December 6, 2024
- Govt Unveils Draft Healthcare Strategy for 2025-2029 with Focus on Drug Innovation
December 6, 2024
- Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
- First Generics of Equa Priced at 30% of Original Product
December 6, 2024
- Mitsubishi, Dewpoint Join Hands on ALS Drug Targeting TDP-43
December 6, 2024
- Nxera Starts PIII Insomnia Drug Trial in South Korea; Data Due Out in 1H 2026
December 6, 2024
- Alzheimer’s Med Leqembi Approved in Mexico
December 6, 2024
- Keytruda Tops Drug Sales Ranking for 14th Month in November: Encise
December 6, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…